Reviewer’s report

Title: Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial

Version: 2 Date: 7 October 2012

Reviewer: Mirte Malingre

Reviewer’s report:

No major compulsory revisions.

Minor essential revisions:

1. What can be the reason for the high pre-dose endogeneous IFN concentrations? Please add possible explanation(s)

2. Discussion: this last result could lead to space the dosage interval for the IFN mixture formulation. The study design was twice a week, is this the best frequency for further studies? Please add some discussion about the probably best frequency for this formulation

3. Discussion pg 14: This is the first PK/PD study in humans with this variety of IFN formulation. Is this correct, see reference no.5?

4. Discussion pg 16: adverse events: were qualitatively similar to those previously reported -> qualitatively? correct word choice? were they similar in severity or / and in percentage? Please clarify.

5. Improve words/sentences:
   pg 7: study design: pharmacodinamyc -> pharmacodynamic
   pg 11 results: twelve patients, 7 females -> add and 5 males
   pg 11: results: no.8 who serum samples were no available -> no.8 whose serum samples were not available

6. Correct word choixes?:
   - synergic? -> synergistic? please check
   - pharmacodinamy? -> pharmacodynamics? please check
   - pg 12 pharmacodynamic analysis: until 0,9 pg/ml regarding pre-dose values -> compared to? please check

Level of interest: An article of importance in its field

Quality of written English: Acceptable
**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests